[{"id":"c03cd6cf-6527-4a1c-bcb8-a257d0066911","acronym":"","url":"https://clinicaltrials.gov/study/NCT03031691","created_at":"2021-01-18T14:55:19.151Z","updated_at":"2024-07-02T16:36:42.138Z","phase":"Phase 1b","brief_title":"A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03031691","lead_sponsor":"OncoMed Pharmaceuticals, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lonsurf (trifluridine/tipiracil) • brontictuzumab (OMP-52M51)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 05/01/2017","primary_completion_date":" 05/01/2017","study_txt":" Completion: 09/01/2017","study_completion_date":" 09/01/2017","last_update_posted":"2020-08-11"}]